CopyPastehas never been so tasty!

The Pharmaceutical Market : Hungary

by anonymous

  • 0
  • 0
  • 0
69 views

 

The government has identified healthcare reform as a top priority and faces the challenge of financing the health sector with a health insurance fund budget that it considers to be inadequate. Hungary spent an estimated 7.1% of GDP on health in 2011. Around two thirds of this is through the public health insurance system, although the private sector is growing through increased co-payments and private insurance schemes. Total health expenditure is expected to grow slightly in US dollar terms between 2011 and 2016. http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/the-pharmaceutical-market-hungary.html

In January 2011, new rules on the opening and operation of pharmacies came into force. Wholesalers, pharmaceutical companies and offshore investors are now prohibited from owning new pharmacies and the stake owned by pharmacists at existing pharmacies must reach 51% by January 2017. Pharmacists cannot own more than four branches. At least 4,000 people will have to be served by each new pharmacy in towns with populations exceeding 50,000. The number increases to 4,500 in smaller towns. Pharmacies must also be at least 250 metres apart. The rules governing pharmacy ownership have become increasingly more restrictive since the government decided to end the pharmacy liberalisation process in July 2010, by prohibiting the opening of new pharmacies, except for in towns that did not have one. The Pharmacy Liberalisation Act of 2007 saw the number of pharmacies increase rapidly, but as the number of redeemed prescriptions remained unchanged, price competition increased, leading to a number of pharmacies finding themselves on the verge of bankruptcy.

The Hungarian pharmaceutical industry concentrates on generic production. Companies such as Gedeon Richter and Egis retain strong positions in the market, and are also prominent in the former Soviet Union. Demand is growing for expensive branded products. Hungary has a number of well-established manufacturers. The largest domestic producer, Gedeon Richter, was founded in 1901, whilst several others, such as Alkaloida, now a part of Sun Pharmaceutical Industries, or Chinoin, were set up in the early 1900s. However, foreign manufacturers also have a presence on the market; the Association of Innovative Pharmaceutical Manufacturers (AIPM) represents 25 research-based pharmaceutical companies, including AstraZeneca, Bayer and Merck. Members of the Hungarian Pharmaceutical Manufacturers Association (MAGYOSZ) include GlaxoSmithKline, Pfizer and Sanofi.

PROVIDING STRATEGIC MARKET ANALYSIS EVERY MONTH
Espicom's highly-regarded world pharmaceutical market research reports provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

Market size and trends impacting the development of the market.
Five-year projections for market indicators such as health spending.
Regulations on drug applications & approvals, pricing & reimbursement as well as wholesaling and retail.
Specialised intelligence on generics and biological medicines.
Foreign and local company profiles

EXECUTIVE SUMMARY.. 1
Snapshot: Strategic Espicom Analysis..2
Snapshot: Key Data Projections .....3
MACROENVIRONMENT. 4
POLITICAL..4
ECONOMIC 5
Projections .5
LEGAL...6
EU Patent Protection & Intellectual Property Rights.....6
Proposal for Unitary Patent 6
National Patent Protection & Intellectual Property Rights .6
EU Supplementary Protection Certificates...6
EU Data Exclusivity7
DEMOGRAPHIC ....7
Projections .7
Demographic Indicators...8
Births... 8
Deaths 8
Infant Deaths. 8
Life Expectancy at Birth 8
EPIDEMIOLOGY. 9
DISEASE BURDEN.9
Leading Causes of Death ..9
DISEASE PREVALENCE...10
Communicable Diseases.10
HIV/AIDS. 11
Non-Communicable Diseases ....11
HEALTHCARE - ACCOMPANYING HEALTH STATISTICS .. 12
EU DIRECTIVE12
Cross-Border Healthcare Directive ..12
ORGANISATION..13
National Health Fund Administration...14
Local Government.....14
Private Healthcare.....15
Healthcare Reform. 15
EXPENDITURE.....16
Projections .....16
Social Security17
INFRASTRUCTURE....18
Hospital Infrastructure ...18
SERVICES..19
Hospital Inpatient Services ..19
Outpatient Services...20
WORKFORCE.21
Projections .....21
Physicians.21
REGULATORY AFFAIRS ..... 22
EU REGULATORY AUTHORITY. 22
NATIONAL AUTHORITY 22
MARKETING REGISTRATION.... 22
EU Marketing Registration...22
Centralised Procedure.22
National Regulation..23
PROMOTION .24
Advertising ....24
PRICING & REIMBURSEMENT. 25
EU NETWORKING MEETING..... 25
NM CAPR...25
PRICING .. 25

For more information kindly visit :
The Pharmaceutical Market : Hungary

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: https://twitter.com/BharatBook
Our Blogs: http://in.linkedin.com/pub/bharat-book/3a/98/512
http://financemarketreports.blogspot.com/

Add A Comment: